Clinical outcomes and Guardant360 circulating tumor DNA profiling in ALK-positive non-small cell lung cancer treated with lorlatinib after alectinib. // JAAD International. – URL: https://www.sciencedirect.com/science/article/pii/S3117504X26000719?dgcid=rss_sd_all
Clinical outcomes and Guardant360 circulating tumor DNA profiling in ALK-positive non-small cell lung cancer treated with lorlatinib after alectinib. JAAD International. https://www.sciencedirect.com/science/article/pii/S3117504X26000719?dgcid=rss_sd_all
“Clinical outcomes and Guardant360 circulating tumor DNA profiling in ALK-positive non-small cell lung cancer treated with lorlatinib after alectinib.” JAAD International.
@article{article5801,
title = {Clinical outcomes and Guardant360 circulating tumor DNA profiling in ALK-positive non-small cell lung cancer treated with lorlatinib after alectinib},
journal = {JAAD International},
url = {https://www.sciencedirect.com/science/article/pii/S3117504X26000719?dgcid=rss_sd_all}
}